Mathijs Bunck

Mathijs Bunck

Company: Eli Lilly & Company

Job title: Associate Vice President, Medical Development, Tirzepatide Obesity

Seminars:

Chair’s Closing Remarks 4:30 pm

Read more

day: Day Two

Innovating Clinical Trial Design to Engage Patients & Optimize Study Outcome
10:45 am

Read more

day: Day 2 Stream 2 AM

Panel Discussion: Agents, Trial Design & Collaboration: Breaking New Ground in Combination Therapy with Multiple Mechanisms of Action 9:30 am

Navigating different combinations of therapeutic agents: what can you combine? Crafting protocols around current standard for care Collaborate to innovate: examining rationale for cross-industry partnerships to forge synergistic combination therapiesRead more

day: Day One

Tirzepatide, Morbidity & Mortality in Obesity: Pioneering a Holistic Approach to Obesity Outcomes Trials 9:00 am

Investigating an unprecedented step forward in weight loss: development of the dual GIP and GLP-1 receptor agonist tirzepatide Moving beyond traditional outcome trials for individual indications to efficiently assess efficacy in obesity, HFpEF, NASH, CKD, and other obesity-related morbidities Navigating a broader primary endpoint and select type-1 error controlled secondary endpoints to study multiple outcomes…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.